CompletedNot Applicable

Sentinel(TM) Post-Market Registry

300 participantsStarted 2014-03

Plain-language summary

The SENTINEL Post-Market Registry is a prospective, multi-center, registry using the CE-Marked Sentinel System in subjects with severe symptomatic calcified native aortic valve stenosis indicated for TAVR. Subjects enrolled in the registry will undergo TAVR + Sentinel. Basic demographic information and detailed procedural data will be captured and documented in a registry case report form. All Sentinel filters will be sent for histopathology at an independent core-lab.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Approved indications for commercially available CE-Marked TAVR devices.
✓. Compatible left common carotid artery (6.5 - 10 mm) and brachiocephalic artery (9 - 15 mm) diameters without significant stenosis (\> 70%).
✓. The subject or the subject's legal representative has been informed of the nature of the registry, agrees to its provisions and has provided written informed consent as approved by the Ethics Committee of the respective site.

Exclusion criteria

✕. Vasculature in the right extremity precluding 6Fr sheath radial/brachial access
✕. Inadequate circulation to the right extremity as evidenced by signs of artery occlusion or absence of radial or brachial pulse
✕. Hemodialysis shunt, graft, or arterio-venous fistula involving the upper extremity vasculature
✕. Patients in whom anti-platelet and/or anticoagulant therapy is contraindicated, or who will refuse transfusion
✕. Excessive tortuosity in the right radial/brachial/subclavian artery preventing Sentinel device access and insertion
✕. Patient whose brachiocephalic or left carotid artery reveals significant stenosis, ectasia, dissection, or aneurysm at the ostium or within 3 cm of the ostium
✕. Currently participating in an investigational drug or investigational (non CE-mark) device study

What they're measuring

Primary Observational Endpoint

Timeframe: Post-Procedure (day 1)

Trial details

NCT IDNCT02255851

SponsorClaret Medical

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2016-05

View on ClinicalTrials.gov More Transcatheter Aortic Valve Replacement trials